Mark Mascolini has been writing about HIV and AIDS since the beginning of the epidemic. Peer-reviewed work he coauthored has appeared in JAIDS, Antiviral Therapy and the Journal of the International AIDS Society.
His work appears regularly on TheBodyPRO.com and the websites of the National AIDS Treatment Advocacy Project (NATAP), AVAC and the Center for AIDS, as well as in Reviews in Antiviral Therapy & Infectious Diseases.
Mascolini has published interviews with scores of leading HIV investigators, including Bernard Branson, Myron Cohen, Kevin DeCock, Anthony Fauci, Robert Grant, David Ho, Daniel Kuritzkes, Joep Lange and Mark Wainberg.
Latest by Mark Mascolini
The diabetes rate is about 4% higher in people with HIV than in the general U.S. population -- highlighting the importance of early monitoring for and prevention of diabetes.
We already know some of the dangers of drinking too much alcohol, but new research suggests that heavy alcohol consumption exacerbates the negative effects of HIV in people living with the virus.
The chance of HIV rebounding after starting and maintaining antiretroviral therapy lies close to 1% per year in certain groups living with HIV, according to a study published in The Lancet HIV.
Compared with moderate alcohol drinkers, people with self-reported or provider-reported heavy drinking ran a higher risk of death, according to a 10-year study.
Most HIV drugs have little or no impact on the effectiveness of hormonal contraceptives, with the possible exception of Sustiva (efavirenz).
Compared with a similar group of HIV-negative men, 50- to 59-year-old men with HIV in a large U.S. study had a doubled risk of fractured bones.
A past pneumonia episode largely explained a higher risk of lung cancer in people living with HIV, according to a large study in California. Smoking and alcohol abuse also contributed to the higher risk.
Quitting smoking can certainly be a tough commitment to make. For HIV-positive smokers who may be struggling to quit, here are 10 things to know.
A third World Health Organization (WHO) option to treat HIV-positive pregnant women -- and to prevent mother-to-child transmission (MTCT) of HIV -- calls for starting triple antiretroviral (ARV) therapy (ART) for all women as soon as they test positi...
Introduction The primary infection experiment Not just "math and modeling" Thinking ahead with anti-HIV regimens "Not a time to pull back" on quest for new drugs The eradication wager References
When attempting to write a pithy preambl...